Francesco RAIMONDI
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (7)
Year:
2026
Basal cell carcinoma (BCC), the most common human cancer, is driven by hyperactivation of the Hedgehog pathway mediated by Smoothened (SMO) signaling and Glioma-Associated Oncogene Homolog (GLI) transcription. Gαs and protein kinase A (PKA) negatively regulate Hedgehog signaling, offering a potential alternative BCC development and treatment pathway. In this study, using histology alongside bulk and single-cell RNA sequencing, we found that mouse BCC–like tumors that originate from Gαs pathway inactivation are highly similar to those driven by canonical Hedgehog signaling induced by constitutive SMO activation. Both pathways led to the expansion of basal stem cells in the skin, with tumor cells clustering in two distinct populations with markers for touch dome and isthmus stem cell–like cells. Interestingly, mutations that reduce Gαs and PKA activity were present in human BCC. Tumors from Gαs pathway inactivation were independent of the canonical Hedgehog regulators SMO and GPR161, establishing them as SMO-independent oncogenic Hedgehog signaling models. Finally, activation of the Gαs-coupled adenosine 2B receptor with BAY60-6583 counteracted oncogenic SMO, reducing Hedgehog signaling and tumor growth. Together, these findings offer a potential therapeutic strategy for BCC. Significance: Gαs/PKA pathway inactivation drives Hedgehog-dependent basal cell carcinoma and can be counteracted by activation of the Gαs-coupled adenosine 2B receptor to suppress tumor growth, providing a potential treatment for Hedgehog-driven tumors.
Year:
2026
Basal cell carcinoma (BCC), the most common human cancer, is driven by hyperactivation of the Hedgehog pathway mediated by Smoothened (SMO) signaling and Glioma-Associated Oncogene Homolog (GLI) transcription. Gαs and protein kinase A (PKA) negatively regulate Hedgehog signaling, offering a potential alternative BCC development and treatment pathway. In this study, using histology alongside bulk and single-cell RNA sequencing, we found that mouse BCC–like tumors that originate from Gαs pathway inactivation are highly similar to those driven by canonical Hedgehog signaling induced by constitutive SMO activation. Both pathways led to the expansion of basal stem cells in the skin, with tumor cells clustering in two distinct populations with markers for touch dome and isthmus stem cell–like cells. Interestingly, mutations that reduce Gαs and PKA activity were present in human BCC. Tumors from Gαs pathway inactivation were independent of the canonical Hedgehog regulators SMO and GPR161, establishing them as SMO-independent oncogenic Hedgehog signaling models. Finally, activation of the Gαs-coupled adenosine 2B receptor with BAY60-6583 counteracted oncogenic SMO, reducing Hedgehog signaling and tumor growth. Together, these findings offer a potential therapeutic strategy for BCC. Significance: Gαs/PKA pathway inactivation drives Hedgehog-dependent basal cell carcinoma and can be counteracted by activation of the Gαs-coupled adenosine 2B receptor to suppress tumor growth, providing a potential treatment for Hedgehog-driven tumors.
Year:
2026
Metastatic uveal melanoma is an aggressive disease with limited effective therapeutic options. To comprehensively map monogenic and digenic dependencies, we performed CRISPR–Cas9 screening in ten extensively profiled human uveal melanoma cell line models. Analysis involved genome-wide single-gene and combinatorial paired-gene CRISPR libraries. Among our 76 uveal melanoma-specific essential genes and 105 synthetic lethal gene pairs, we identified and validated the CDP-diacylglycerol synthase 2 gene ( CDS2 ) as a genetic dependency in the context of low CDP-diacylglycerol synthase 1 gene ( CDS1) expression. We further demonstrate that CDS1 / CDS2 forms a synthetic lethal interaction in vivo and reveal that CDS2 knockout results in the disruption of phosphoinositide synthesis and increased cellular apoptosis and that re-expression of CDS1 rescues this cell fitness defect. We extend our analysis using pan-cancer data, confirming increased CDS2 essentiality in diverse tumor types with low CDS1 expression. Thus, the CDS1/CDS2 axis is a therapeutic target across a range of cancers.
Year:
2025
Year:
2025
We present the CellHit web server (https://cellhit.bioinfolab.sns.it/), a web-based platform designed to predict and analyze cancer patients’ responsiveness to drugs using transcriptomic data. By leveraging extensive pharmacogenomics datasets from the Genomics of Drug Sensitivity in Cancer v1 and v2 (GDSC) and Profiling Relative Inhibition Simultaneously in Mixtures (PRISM) and transcriptomic data from the Cancer Cell Line Encyclopedia (CCLE) and The Cancer Genome Atlas Program (TCGA). CellHit integrates a computational pipeline for preprocessing, gene imputation, and robust alignment between patient and cell line transcriptomic data with pre-trained SOTA models for drug sensitivity prediction. The pipeline employs batch correction, enhanced Celligner methodology, and Parametric UMAP for stable and actionable alignment. The intuitive interface requires no programming expertise, offering interactive visualizations, including low-dimensional embeddings and drug sensitivity heatmaps for the input transcriptomic samples. Results feature contextual metadata, SHAP-based feature importance, and transcriptomic neighbors from reference datasets, simplifying interpretation and hypothesis generation. CellHit provides precomputed predictions across TCGA samples and offers the ability to run custom analyses online on input samples, democratizing precision oncology by enabling rapid, interpretable predictions accessible the research community.
Year:
2025
The Leucine-rich repeat kinase 2 (LRRK2) not only plays a vital role in familial forms of Parkinson’s disease (PD) but is also considered as a risk factor for idiopathic PD. Its multi-domain architecture enables a fine-tuned regulation of its biological function by orchestrating intra- and inter-molecular interactions. Here, we present BioID proximity proteomes of LRRK2 revealing new interactors, which we further characterized by a novel evolutionary and structural bioinformatics pipeline. Co-evolutionary analysis of the protein-protein interaction network identified a structural and functional module enriched in cytoskeletal components linked to the centrosome and microtubules. Furthermore, structural modelling of binary interactions via AlphaFold-multimer revealed distinct groups of interactors engaging with LRRK2 dependent on specific conformations and epitopes. Furthermore, we identified distinct changes in the LRRK2 proximity proteome induced by the type I kinase inhibitor MLi-2 or by co-expression of the LRRK2 upstream effector RAB29. Dependent on its state of activity and conformation, these protein-protein interactions link LRRK2 to defined cellular sub-compartments, including centriolar satellites as well as vesicular sub-compartments.
Year:
2024
Collaborators (8)
Roberto Weigert
Senior Investigator
National Institutes of Health
Kavita Y. Sarin
-
Saikat Mukhopadhyay
Associate Professor, W.W. Caruth, Jr. Scholar in Biomedical Research
University of Texas Southwestern Medical Center
Yeap Ng
National Institutes of Health
Christian Johannes Gloeckner
Group Leader
Deutsches Zentrum für Neurodegenerative Erkrankungen
Francesco Carli
Staff scientist
European Bioinformatics Institute
Larissa Matsuyama
Postdoctoral Fellow
Wellcome Sanger Institute
Marius Ueffing
University of Tuebingen
Make your next move.
Prepare your application
Review drafts before you send them.